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ABSTRAK
Pandemi obesitas dan diabetes mellitus (DM), khususnya DM tipe 2 (DMT2) kini menjadi ancaman yang 
serius bagi umat manusia di dunia. International Diabetes Federation (IDF) menyebutkan bahwa prevalensi 
DM dunia adalah 1,9% dan telah menjadikan DM sebagai penyebab kematian urutan ke-7 dunia. Proyeksi 
prevalensi diabetes tahun 1994 sampai 2010 diperkirakan 215,6 juta jiwa, namun dari evaluasi tahun 2007 
jumlah penderita diabetes sudah mencapai 246 juta jiwa bahkan tahun 2025 dikhawatirkan jumlah tersebut 
akan meningkat sampai lebih dari 300 juta jiwa.
Pasien DM berpotensi menderita berbagai komplikasi, meliputi penyakit makrovaskular (penyakit 
jantung, stroke, dan penyakit pembuluh darah tepi) dan penyakit mikrovaskular (retionopati, neuropati, 
dan nefropati). Komplikasi DM sudah dimulai sejak dini sebelum diagnosis DM ditegakkan. Sekitar 50% 
pasien ketika didiagnosis telah menyandang satu komplikasi kronik. Karena itu, perlu adanya panduan yang 
dapat menatalaksana prediabetes terkait dengan pencegahan risiko komplikasi kronik diabetes dan risiko 
kardiovaskular. Panduan ini diharapkan dapat menambah keahlian tenaga medis untuk mengenali prediabetes, 
mengidentifikasi orang-orang dengan risiko tinggi diabetes, dan memberikan penatalaksanaan yang tepat agar 
kejadian DM dan komplikasinya dapat dikurangi.
Kata kunci: diagnosis, risiko, prediabetes, diabetes mellitus, penatalaksanaan.
ABSTRACT
Pandemic obesity and diabetes mellitus (DM), particularly type-2 DM (T2DM) now has become a serious 
threat for people worldwide. The International Diabetes Federation (IDF) suggests that the prevalence of DM 
in the world is 1.9% and it has made DM as the 7th leading cause of death worldwide. It has been estimated 
that the prevalence of diabetes between 1994 and 2010 was projected as much as 215.6 milion people; however 
an evaluation in 2007 revealed that the number of diabetic patients has reached 246 million people and it has 
been concerned that the number would increase in 2025 reaching more than 300 million people.
Patients with DM may have various complilcations, including macrovascular diseases (heart disease, 
stroke and peripheral vascular disease) and microvascular diseases (retinopathy, neuropathy and nephropathy). 
Complications of DM have started early before the diagnosis of DM has been made. About 50% of patients have 
alreadly had one chronic complication at the time of diagnosis. Therefore, it is necessary to have a guideline 
on management of prediabetes condition associated with prevention of chonic complication and cardiovascular 
risk of diabetes. The guideline is expected to improve the skills of health care professionals in recognizing 
prediabetes condition, identifying people at high risk for diabetes and providing an appropriate management 
so that the incidence and complication of DM can be reduced.
Key words: diagnosis, risk, prediabetes, diabetes mellitus, management.
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INTRODUCTION
Results of basic health care research/riset 
kesehatan dasar (RISKESDAS) reported by 
Department of Health Care in 2008 revealed 
that the prevalence of DM in Indonesia at that 
time was 5.7%. According to WHO, the number 
of diabetic patients in Indonesia will increase 
from 8.4 million people in 2000 and it will 
become 21.3 million people in 2030. The high 
morbidity rate has made Indonesia on the 4th 
rank worldwide after China, India and United 
States. Without prevention measures and an 
effective controlling program, the prevalence 
will be continuously increasing.1
Patients with DM may have various 
complilcations, including macrovascular diseases 
(heart disease, stroke and peripheral vascular 
disease) and microvascular diseases (retinopathy, 
neuropathy and nephropathy).2 Complications of 
DM have started early before the diagnosis of 
DM has been made. About 50% of patients have 
already had one chronic complication at the time 
of diagnosis, 21% among them have retinopathy, 
18% have an abnormal electrocardiogram 
(ECG) findings, and 14% have impaired blood 
flow to the limb causing undetected limb pulse 
or leg ischemia. Those various complications 
of diabetes has caused modified lifestyle and 
reduced life expectancy in individuals with 
DM. The life expectancy rate has become 
15 years lower and 75% of them died due to 
macrovascular complications.3,4 In keeping with 
the development of normal glucose tolerance 
into obvious DM, the morbidity and mortality 
associated with diabetes and its complication 
has also been increasing.5
Blood glucose level is a continuous spectrum. 
The limit of blood glucose levels considered as 
normal, prediabetes and diabetes is determined 
arbitrarily based on a consensus. Currently, the 
diagnosis of diabetes is established when the 
fasting blood glucose level is >126 mg/dl or 
when the 2-hour postprandial blood glucose 
level >200 mg/dl. In oral glucose tolerance 
test (OGTT), it is determined based on blood 
glucose level associated with the development 
of microangiopathy complications, which have 
specific characteristics for diabetes, particularly 
retinopathy. Prediabetes is diagnosed when the 
blood glucose level is above normal but still 
below the blood glucose level for diabetes. The 
diagnosis of prediabetes is established when the 
fasting blood glucose level is 100-125 mg/dl 
(impaired fasting glucose = IFG) or when the 
2-hour postprandial blood glucose level is 140-
199 mg/dl (impaired glucose tolerance = IGT), 
or both (impaired glucose homeostasis = IGH).6,7
Based on observations, individuals with 
prediabetes may develop into 3 possibilities: 
approximately 1/3 of cases will develop into 
T2DM, the other 1/3 of cases will stay unchanged 
as prediabetes and the other remaining 1/3 cases 
may be back to normoglycemia condition. 
Prediabetes condition raises absolut risk by 2- 
to 10-fold; moreover, the risk of cardiovascular 
disease in prediabetes is comparable with DM. 
Those conditions provide more convincing 
facts that early prevention measures and 
programs of DM is very essential, inter alia 
through management of prediabetes condition, 
identification and early management of patients 
with prediabetes condition that may reduce the 
incidence and complications of DM, which will 
be very useful not only for patients, but also their 
families and the government.8
Different epidemiological data between 
IGT and IFG shows that there are different 
mechanisms of pathophysiology of both 
conditions. Although the determination of IGT 
and IFG is made based on insulin resistance, 
but both show differences on the site of insulin 
resistance occurs. Insulin resistance in IFG 
is mainly occurs in liver; while the insulin 
sensitivity in muscle tissues is still normal. In 
IGT, insulin sensitivity in the liver stays normal 
or slightly reduced; while in the muscle tissues, 
the insulin resistance has occurred. The patterns 
of insulin resistance in both conditions are also 
different. In IFG, phase-one reduced insulin 
secretion occurs (in the first 10 minutes) after 
intravenous glucose is given and initial-phase of 
reduced response of insulin secretion (in the first 
30 minutes) after oral glucose administration; 
while the delay-phase of insulin secretion (60-
120 minutes) during the OGTT stays normal. In 
IGT, there is also impaired initial-phase insulin 
secretion after oral glucose administration, 
which is accompanied by significant decrease on 
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end-phase of insulin secretion.9 Type-2 diabetes 
emerges due to progressive impairment of insulin 
secretion with a background of insulin resistance. 
Both impairment of insulin secretion and insulin 
resistance have been affected by genetic and 
environment risk factors, which also includes 
the embryonic environment. Obesity, particularly 
central obesity, is one of the most important risk 
factors for type-2 diabetes.
Obesity may cause insulin resistance 
through two mechanisms, i.e.: secretion of 
various adipokines (Tumor Necrosis Factor)5,6,8 
Until now, there is no recommendation on 
management of prediabetes in Indonesia. 
This guideline discusses the aims and goals 
of prediabetes management associated with 
prevention of diabetes chronic complication 
risks and cardiovascular risks. By having 
this guideline, health care professionals are 
expected to have improved skills in recognizing 
prediabetes condition, identifying people 
at high risk for diabetes and providing an 
appropriate management so that the incidence 
and complication of DM can be reduced.
DIAGNOSIS AND RISK FACTORS OF 
PREDIABETES
Diagnosis
Prediabetes (IFG and/or IGT) is diagnosed 
according to WHO recommendation. Diagnosis 
of IFG is made when the blood glucose level after 
8-to 10-hour fasting is 100–125 mg/dl. Diagnosis 
of IGT is established when the blood glucose 
level after 2-hour postprandial challenge with 75 
gram glucose is between 140 and 199 mg/dl.6,7,10
Preparation and procedures of OGTT 
according to WHO (appendix):
- Preparation. In the days before the test, the 
patient is instructed to consume carbohydrate 
intake in adequate amount. On the test day, 
patient should not do excessive physical 
activities or having caffeine intake or other 
drugs that may affect blood glucose level. 
- Procedures
- Patient is instructed to fast for at least 8 
hours. 
- Blood is withdrawn first for measurement 
of fasting blood glucose
- Subsequently, the subject is given 75 
gram glucose solution in 300 cc water to 
drink 
- 2 hours after the glucose loading, blood 
is drawn for measurement of 2-hour 
postprandial or post challenge glucose 
level.11
Table 1. Diagnosis criteria for prediabetes
Impaired Fasting Glucose (IFG), whenever:
 - Fasting blood glucose level is 100-125 mg/dl (5.6-
6.9 mmol/L)
 - 2-hour postprandial blood glucose level is <140 mg/
dL
Impaired Glucose Tolerance (IGT), whenever: 
 - Normal fasting blood glucose level is <100 mg/dL
 - After 75 gram glucose challenge, the 2-hour 
postprandial blood glucose level is 140-199 mg/dL, 
(7,8-11 mmol/L)
Prediabetes, if there is IFG and/or IGT
Not all of various epidemiological studies 
have incorporated the use of 2-hour postprandial 
blood glucose level to establish the diagnosis of 
prediabetes and only use the fasting blood glucose 
level. It may result in false negative since the IGT 
would be undetected. Individuals with normal 
fasting blood glucose would be categorized as 
IGT when OGTT is performed. Detecting the 
presence of IGT should be performed considering 
that it may develop into T2DM and higher risk 
of cardiovascular complication in subjects with 
IGT than individuals with IFG.2,10
Several cardiovascular risk factors are 
found concomitantly along with risk factors of 
diabetes in an individual. Those risk factors are: 
obesity, hypertension, a low cholesterol level 
of high density lipoprotein (HDL), increased 
triglycerides level, and glucose metabolism 
disorder, which is known as the metabolic 
syndrome. Metabolic syndrome is considered 
to a prediabetes equivalent. Approximately 50% 
patients with IGT meet the National Cholesterol 
Education Program – Adult Treatment Panel III 
(NCEP-ATP III) criteria for the diagnosis of 
metabolic syndrome.5,11,12
Risk Factors for Prediabetes
Risk factors for prediabetes are similar with 
the risk factors for the development of T2DM. 
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Those risk factors can be categorized into 
modifiable and non-modifiable risk factors. The 
most important factors are obesity (particularly 
abdominal obesity) and lack of physical activity. 
Non-modifiable risk factors: 
a. Genetic factors. Until now, genes associated 
with the risk for DM have not been confirmed. 
However, there is an obvious difference of 
DM event among different ethnic groups 
although they live in the same environment, 
which indicates that genetic factor may have 
considerable contribution in the development 
of DM (Alberti et al, 2007).8
b. Age. The prevalence of DM is increasing 
with age. In the last decades, the age of DM 
onset has decreased, particularly in countries 
with an imbalance between energy intake and 
output.
c. Gestational diabetes. In gestational diabetes, 
glucose tolerance returns to normal after 
birth; however, the woman is at risk of 
developing DM in the future.8
Modifiable risk factors: 
a. Obesity. Obesity is the most important risk 
factor. Some longitudinal studies show 
that obesity is a strong predictor for the 
development of T2DM. Furthermore, an 
intervention aimed to reduce obesity may 
actually also reduce the incidence of T2DM. 
Various longitudinal studies have also 
demonstrated that waist circumference or 
waist-to-hip ratio which represents visceral 
(abdominal) fat condition, is actually a better 
indicator than body mass index as the risk 
factor for prediabetes. Those data confirm 
that fat distribution is more important than 
the total amount of fat.
b. Physical activities. In last decades recently, 
reduced intensity of physical activities 
in various populations has been a great 
contributor to increased obesity worldwide. 
Various cross-sectional and longitudinal 
studies have shown that reduced physical 
activity is an independent predictor for the 
development of T2DM either in men or 
women.
c. Nutrition. High total caloric intake, low 
fiber diet, high-glycemic load and low 
ratio of polyunsaturated fatty acid (PUFA) 
to saturated fats are risk factors for the 
development of DM.
d. Other risk factors. Although genetic factor 
and lifestyle have been the greates risk 
factors for the development of DM, some risk 
factors are modifiable including low birth 
weight, exposure to intrauterine diabetic 
environment and some of inflammatory 
components.8
Blood Glucose Spectrum and Cardiovascular 
Risks
Blood glucose spectrum. Actually, blood 
glucose level is a continuous spectrum between 
the glucose level considered normal (fasting 
glucose level of <100 mg/dl; postprandial 
glucose level of <140 mg/dl) and the level of 
blood glucose, which is considered as diagnostic 
for diabetes (fasting glucose level of >126 mg/
dl; postprandial glucose level after 75 gram 
glucose challenge of >200 mg/dl). The limits of 
those blood glucose levels are associated with the 
onset of complications specific for diabetes (end-
organ complication), particularly the retinopathy. 
Various population studies indicate that values 
of fasting blood glucose level and the 2-hour 
postprandial glucose levels associated with 
the development of complication are actually 
lower than the threshold limit of blood glucose 
level used currently for diagnosing diabetes. 
It is assumed that despite the blood glucose 
level still below the “normal” threshold limit, 
the individual may already have increased risk 
for microvascular and macrovascular diabetes 
complications.11
The natural history of illness shows that 
6-10% patients with IGT will have progression 
to diabetes in 1 year period of time; while for 
patients with both IGT and IFG, the cumulative 
incidence of diabetes by 6 years is as much as 
60%. In addition, for individuals with normal 
glucose tolerance level, the incidence of diabetes 
is only about 5%.
Prediabetes and risks for cardiovascular 
disease (CVD). Various studies demonstrated 
a linear correlation between glycemia status 
and the risks for CVD. Subjects in prediabetes 
group had an equal risk for the development 
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of complication as subjects in diabetes group. 
Regarding diabetes and CVD risks in the 
prediabetes group, IGT is more associated with 
both risks compared to those with IFG.4
The results of epidemiologic studies 
on CVD incidence rate, such as AusDiab 
(Australian diabetes, obesity, and lifestyle study), 
Framingham Study and intervention studies such 
as Study to Prevent Non-Insulin-Dependent 
Diabetes Mellitus (STOP-NIDDM) and Diabetes 
reduction Assessment with Ramipril and 
Rosiglitazone Medication (DREAM) study, 
suggest that cardiovascular risk in individuals 
with IFG and IGT doubles compared to those 
without IFG or IGT.3 The results of The Nurse 
Health Study showed that women destined 
to convert to T2DM have 3 times the risk of 
CVD risks compared to those remained as non-
T2DM individuals. A meta-analysis conducted 
by Levitan et al confirmed that prediabetes is 
associated with increased fatal and non-fatal risk 
of CVD. The increased risks were comparable 
between individuals in IFG and IGT groups. 
Cardiovascular risks increased with linear 
pattern when associated with blood glucose level 
after meal; while when it was associated with 
fasting blood glucose, the assumed threshold of 
increased risk was 99 mg/dl.13
A cohort study of The Diabetes Epidemiology 
Collaborative Analysis of Diagnosis Criteria 
in Europe (DECODE) and a similar study in 
Asia (DECODA) have also found that the 
2-hour postprandial glucose level after glucose 
challenge is a better predictor for cardiovascular 
mortality than fasting glucose level. Moreover, 
other various studies have also demonstrated 
a association of postprandial hyperglycemia 
with increased risk of retinopathy, thickening 
of carotid intima-media layers, endothelial 
dysfunction, oxidative stress, inflammation, 
reduced blood flow volume to cardiac myocytes, 
cognitive impairment in elderly and increased 
risk for cancer.4
A REVIEW OF STUDIES ON DM PREVENTION 
Some immediate measures of prevention are 
necessary to reduce the number of patients with 
prediabetes, T2DM and cardiovascular disease 
associated with diabetes. Those prevention 
measures include:
Lifestye intervention
Lifestyle modification should be the core of 
treatment and it should be provided to all patients 
even should be reinforced in every patient’s 
visit. Lifestyle is a fundamental management 
approach that can effectively prevent or delay 
the progression from prediabetes to diabetes, 
as well to reduce both microvascular and 
macrovascular disease risks. More importantly, 
lifestyle interventions improve all risk factors 
for diabetes and components of the metabolic 
syndrome, obesity, hypertension, dyslipidemia 
and hyperglycemia. In accordance with the 
Diabetes Prevention Program (DPP) findings, 
patients with prediabetes should reduce weight 
by 5% to 10% and should maintain this level 
for a long-term. A moderate degree of weight 
loss results in reduced fat mass, decreased 
blood pressure, glucose, low density lipoprotein 
(LDL) cholesterol and triglycerides levels. 
These benefits can also appear in long-term 
outcome, especially if weight loss and lifestyle 
intervention are maintained. A long-term follow-
up in a Finish Diabetes Prevention Program 
showed that lifestyle intervention in patients at 
high risk for T2DM has resulted in reduction in 
diabetes incidence, which persisted even after 
the individual lifestyle counseling was stopped.6,8
A program of regular moderate-intensity 
physical activity for 30 to 60 minutes daily, at 
least 4 days weekly or minimal 150 minutes/
week, is recommended.8
The recommended diet includes calorie 
restriction, increased fiber intake and limitations 
in carbohydrate intake. Specifically for patients 
with hypertension, dietary recommendations 
include lower sodium intake and limitation in 
alcohol consumption.6,8
Although adjustment on individual basis 
may be necessary, lifestyle modification can 
be recommended for all ages but it may be 
difficult to maintain. Physicians should focus 
and emphasize on the importance of maintaining 
weight loss as the long-term goal. Some efforts 
expected to increase the likelihood success are: 
patient self-monitoring, realistic and stepwise 
goal setting, social support, reinforcement on the 
importance of healthy lifestyle.8 The following 
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studies demonstrate the benefit of lifestyle 
intervention as an effective prevention measure: 
Malmo Study. This study was a preliminary 
study about the role of lifestyle intervention on 
T2DM prevention in Sweden; the study was 
conducted in men aged 47-49 years old. Some 
patients with prediabetes and normal glucose 
tolerance (NGT) received usual care/treatment; 
while patients with prediabetes and the other 
T2DM underwent a lifestyle intervention. 
Those who received lifestyle intervention had 
demonstrated a lower incidence of T2DM 
compared to the group receving usual treatment 
and had reversal of IGT to normal value. At the 
12-year follow-up, patients in prediabetes group 
who received lifestyle intervention showed no 
difference in mortality rate when compared to 
those in the NGT group. Moreover, the mortality 
rate was less than half of men who did not 
received lifestyle intervention.8
Da Qing Study. The Da Qing study examined 
the effect of 6-year diet and exercise intervention 
in Chinese subjects with a mean age of 45 years 
and prediabetes. The diet intervention alone 
reduced the risk of developing type-2 DM of 
31%; while the invertention of physical activity 
alone reduced the risk about 46%. A combination 
of diet and physical activity reduced the risk as 
much as 42%.8
The Finnish Diabetes Prevention Study. It 
was the first randomized trial which specifically 
evaluate the effect of lifestyle intervention on 
T2DM prevention. This lifestyle intervention 
was followed for 3.2 years and it was joined by 
522 overweight/obese subjects with IGT and a 
control group without lifestyle intervention.
Lifestyle intervention was provided by 
individualized counseling focused on achieving 
and maintaining ideal body weight, reducing fat 
intake and increasing fiber intake and increasing 
physical activity. After 2 years of follow-up, the 
incidence of DM reduced as much as 50% in the 
intervention group compared to those in control 
group. The study also reported that the effect of 
lifestyle modification in reducing DM incidence 
may last for at least 4 years after the intensive 
intervention study completed.8
Diabetes Prevention Program (DPP). DPP 
is one of the largest randomized clinical trials, 
which included 3234 individuals with prediabetes 
in Amerika involving women (68%) and 
minorities (45%). The study compared lifestyle 
intervention and drug intervention (metformin) 
with a control group over 2.8 years. The study 
reported that both lifestyle modification and 
metformin had positive effects on DM prevention 
and restoring the prediabetes into a normal 
condition. Furthermore, it is known that lifestyle 
intervention was more effective than metformin. 
There was a lower mortality rate in the group 
with lifestyle intervention compared to those 
receiving metformin. The cost-effectiveness of 
generic metformin is comparable with lifestyle 
intervention without using any medication.
Results of DPP study published afterward 
suggested that an increase of physical activity 
in individuals without weight loss helps them to 
maintain body weight and independently reduces 
diabetes risks. In addition, there was also positive 
effect on fasting glucose and post-prandial 
glucose tolerance. Lifestyle intervention has 
also improved lipid parameters of the metabolic 
syndrome and reduced the risks of hypertension.8
Indian Diabetes Prevention Program 
(IDPP). IDPP was a prospective community-
based study that examined whether lifestyle 
interventions and medication could influence the 
progression to DM in Asian-Indians population 
with IGT who were leaner and more insulint 
resistant than other population (multiethnic 
American, Finnish and Chinese population). The 
results showed that progression of IGT to DM in 
the population was high.
Both lifestyle modification and metformin 
may significantly reduce the development of IGT 
to T2DM; however, there was no added benefit 
from combining them compared to separate 
treatment alone. With lifestyle modification, 
metformin and combination of both treatment, 
the risk of DM was reduced by 28.5%, 26.4%, 
and 28.2%, respectively.8
Pharmacologic Intervention
In reality, lifestyle modification is very 
difficult to be applied without help and monitoring 
from a professional health care practitioner. The 
potential parameter to determine successful 
lifestyle intervention is reduced body weight of 
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2 kg in 1 month or 5% body weight reduction 
in 6 months. It is similar to reduced glucose 
plasma level as the expected response of lifestyle 
intervention. However, not all of individuals at 
high risk can accept lifestyle modification and 
to achieve this goal, another intervention is 
necessary, i.e. with medication. 
Pharmacologic intervention for DM 
prevention is usually recommended as secondary 
intervention to follow or to be use in conjunction 
with lifestyle modification intervention. If with 
lifestyle intervention, the weight loss has not 
occurred, then the use of medication should be 
started.8,14
Metformin. The rationale for the use of 
metformin is largely based on its 40-year-long-
term safety record. The data on safety was 
obtained through results of the DPP and IDPP 
studies. Results of DPP showed that metformin 
in the dose of 850 mg twice daily with meals 
reduced the development of DM by 31% and 
the development of metabolic syndrome by 17% 
in 2.8 years compared to placebo. The relative 
risk reduction was found more obviously in the 
group with body mass index (BMI) >30 kg/
m2. The reduction of relative risk in this group 
reached 16-35%; while those with BMI of 22-
30 kg/m2, the relative risk reduction was only 
as much as 3%.
Different results were found in IDPP, which 
showed a benefit with metformin in those with 
BMI <30 kg/m2 considering that obesity in 
Asians presents at a lower BMI, i.e. >25 kg/m2. 
However, metformin is not recommended for 
everyone with IGT. It may cause lactic acidosis 
(ischemic disorder in kidney and liver). DPP 
results also demonstrated that metformin was less 
effective in DM prevention in individuals aged 
>65 tahun. Metformin limitation may also be 
caused by gastrointestinal side effects, which can 
be overcome by increasing the dose gradually.8
Acarbose. Acarbose acts by inhibiting 
enzymes that digest carbohydrate. In the study 
of STOP-NIDDM with 3.3 years of follow-up, 
acarbose reduced the risk for DM as much as 
25% and the risk for cardiovascular disease as 
much as 49%. The presence of gastrointestinal 
side-effects have caused a 31% drop-out rate 
(vs. 19% in the placebo group); therefore, 
these facts limited its use for DM prevention. 
STOP-NIDDM study results recommend the 
use of acarbose in those who can tolerate the 
gastrointestinal side-effects for DM prevention 
and cardiovascular risk reduction.15
In China, Japan and other Asian countries, 
acarbose is often used as the first line drug for 
patients with newly diagnosed type 2 DM. It is 
also applied for countries with high consumption 
of complex carbohydrates. 
In some patients, acarbose may reduce body 
weight. Results of long-term studies in patients 
with IGT and T2DM showed that acarbose 
significantly reduced body weight of 0.7 – 0.9 kg. 
In STOP-NIDDM study, the incidence of newly 
diagnosed hypertension has also reduced by 
34%. Acarbose may also reduce the lipid levels, 
particularly the fasting lipid and triglycerides 
levels of 15%. Acarbose may also reduce 
atherogenicity of LDL in patients with IGT.8,15
Glitazones. In the DPP, troglitazone 
treatment was withdrawn after about one year 
due to hepatotoxicity. In the Troglitazone 
in prevention of diabetes (TRIPOD) study, 
troglitazone treatment for more than 3 years 
has caused cummulative reduction in incidence 
of diabetes to zero point. Results of a cohort 
study (DREAM study) using rosiglitazone and 
ramipril with a large number and multiethnic 
population showed that subjects in IFG and/or 
IGT group who had received rosiglitazone for 3 
years showed a 60% decrease in progression to 
diabetes compared to 25% in placebo group and 
70% among them returned to normal glucose 
tolerance. The group receiving rosiglitazone 
showed a higher likelihood of significant body 
weight increase and increased incidence of 
congestive heart failure.8,16
Orlistat. Orlistat is a drug acts by a 
mechanism of inhibiting enzyme that breaks 
down triglycerides in the intestine. Results of 
one study showed that orlistat may cause weight 
loss of 3-5 kg over 6 months, which could be 
maintained over 4 years. Treatment of obese 
subjects with IGT by orlistat as an adjuvant 
treatment to diet and lifestyle modification can 
reduce the risk of developing T2DM. In Xenical 
in the Prevention of Diabetes in Obese Subjects 
(XENDOS) study, all of 3304 non-diabetic obese 
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subjects received intensive lifestyle modification 
and were randomized into either orlistat or 
placebo group. After 4 years, the orlistat group 
had 6.9 kg weight loss; while the placebo group 
had 4.1 kg weight loss. The weight loss was 
associated with reduced risk for developing 
DM as much as 37%. The high number of drop 
out (52%) in the orlistat group was associated 
with gastrointestinal side-effects and therefore, 
limiting its use.8
Poly-e-pill. Considering the high probability 
on classification of various risk factors for T2DM 
and CVD (obesity-metabolic syndrome) in one 
individual, the concept of “polypill” - one drug 
that can manage all of those various risk factors 
- has been attractive for the experts since a long 
while ago. However, until now, the expectation 
to find the abovementioned drug has not been 
satisfied. Actually, the concept of polypill 
is integrated in physical activity (exercise). 
Physical activity has been proven to be relatively 
safe (almost without any side effects). It can be 
applied for all ages with dose-dependent results 
and inexpensive. It also contributes a good effect 
on targets at molecular level of all components 
for obesity and metabolic syndrome.
A systematic review and meta-analysis 
comparing lifestyle intervention and drug 
treatment showed that both interventions may 
lower the progression of prediabetes to diabetes 
with equal effectiveness.17
STRATEGY FOR DIABETES MELLITUS 
PREVENTION
Results of studies showed that early detection 
and intervention to improve glucose control 
and to prevent the progression of prediabetes 
to T2DM in individuals at high risk will 
results in reduced incidence, comorbidity and 
complication of diabetes. According to the 
IDF, T2DM prevention strategy is based on 
controlling modifiable risk factors (modifiable 
risks). The prevention strategy can be categorized 
into 2 target groups.8
A High-Risk Population
The high-risk approach:
The IDF proposes a three-step plan for 
T2DM prevention for those in in high-risk group:
- Step 1: identification of those groups who 
may be at high risk
- Step 2: measurement of risk
- Step 3: Intervention
Step 1. Identification of high-risk group
The first step is the identification of 
individuals who have higher risk than average 
population. The IDF recommend the use of 
opportunistic screening by health-care personnel 
(genereal physicians, nurses and pharmacists).
Strategies to predict future risk of diabetes 
usually use demographic and clinical data from 
prospective cohort studies, statistical models and 
risk scores. In the first step, the strategy usually 
has not relied on measurements of blood glucose 
but has utilized various personal measures or 
family history of high blood glucose level. 
In longitudinal approach, age and history of 
high blood glucose level appear to be the most 
important data.
In general, these strategies can not be applied 
for different population due to differences in 
population characteristics. For different ethnic 
group, different strategies are recommended.
Questionnaire is a simple, practical, non-
invasive and inexpensive method to identify 
individuals at high risk for prediabetes and 
diabetes. It is also used to reduce the application 
of OGTT. The IDF recommend the use of brief 
questionnaires to help health-care professonals 
to quickly identify population at high risk that 
need further investigation. The questionnaire can 
also be used for self-assessment.8
Some criteria that should be included in the 
questionnaire:
- Central obesity is most easily calculated by 
measuring abdominal circumference with 
cut-off points that are gender and ethnic 
group specific (Table 2). 
- The presence of family member diagnosed 
with diabetes
- Age >35 tahun
- Cardiovascular history 
- History of hypertension and/or heart disease
- Gestational history 
- Previous occurrence of gestational diabetes
- History of treatment. Use of drugs that 
predispose type-2 DM, including: nicotinic 
acid, glucocorticoids, thyroid hormones.
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If there are some items present in an 
individual at high risk, further investigation 
should be undertaken to evaluate the level of 
risk.8
Step 2. Measuring level of risk
If a person is at high risk for type-2 diabetes, 
we will proceed to step 2. At this stage, other risk 
factors are assessed and determined.
The measurement for level of risk is 
performed by health-care professionals. The key 
investigation in the step 2 is the measurement of 
blood glucose level.
- Plasma glucose. Measurement of blood 
glucose level with glucose challenge will 
not only able to detect IFG or IGT cases, but 
also cases of undiagnosed diabetes. Positive 
findings of IFG and/or IGT may increase the 
risk for progression to T2DM. Interventions 
aimed for individual target provide an 
opportunity to delay or prevent the onset of 
T2DM. 
- Other risk factors include: increased abdominal 
circumference, hypertension, family history 
of diabetes, increased triglycerides/TG 
level or previous cardiovascular disease 
(Table 2). Furhter investigation on other 
cardiovascular risk factors should also be 
performed such as HDL cholesterol, LDL 
cholesterol, and smoking. The presence of 
the abovementioned factors can increase 
the risk of developing diabetes and those 
individuals should receive appropriate 
treatment.8
Step 3. Intervention
Various substantial evidences showed that 
lifestyle modification can prevent the progression 
of prediabetes to T2DM. Therefore, lifestyle 
modification must be the initial intervention for 
all patients. For patients who can not change 
their lifestyle sufficiently and those with a 
high level of risk (for developing diabetes), 
pharmacotherapy should be encouraged along 
with lifestyle modification. Lifestyle changes 
should be maintained since it will continue to 
deliver long-term health benefits.
- Lifestyle modification (lifestyle changes). In 
order to prevent or delay the development 
of diabetes, lifestyle modification should 
be the first choice measure for all patients. 
The lifestyle modification must be 
emphasized in each visit. In addition to its 
effectiveness in preventing the development 
of T2DM, lifestyle modification can also 
improve risk factors for diabetes and other 
components of metabolic syndrome such 
as obesity, hypertension, dyslipidemia, and 
hyperglycemia.
- Weight. Obesity, particularly abdominal 
obesity is “central” to the development 
of T2DM and other associated disorders. 
Therefore, abdominal obesity has become 
a focus of attention in reducing the risk of 
T2DM. In short term period, weight loss 
improves insulin resistance, hyperglycemia 
and dyslipidemia as well as reduces 
hypertension. Patients should be encouraged 
to achieve and maintain a healthy body 
composition. A structured approach of 
long-term weight loss program as has been 
taken in DPP study can reduce 5-7% of 
initial baseline body weight. The target 
is gradual weight loss (0.5-1.0 kg/week) 
through calorie restriction and increased 
physical activity. A self-monitoring of 
weight and waist circumference must be 
performed daily/weekly. Standard weight-
loss diet recommend reducing daily intake 
calorie by 500 – 1000 calorie (depending 
on gender and age), which is aimed to 
maintain body weight. Although very-low 
calorie diet and meal-replacement plans 
can produce impressive results in short-
Table 2. Other risk factors for diabetes
Risk factors
Triglycerides >150 mg/dl (>1.7 mmol/L)
HDL cholesterol Male <40 mg/dl (<1.03 
mmol/L)
Female <50 mg/dl (<1.29 
mmol/L)
or dyslipidemia on treatment
Waist circumference Male >90 cm
Female >80 cm
Blood pressure >130/80 mmHg
or hypertension on 
treatment
Family history of DM Father / mother / siblings
Preexisting heart disease CHD, cerebrovascular 
disease, peripheral arterial 
disease
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term period, but the long-term benefits are 
limited. A complete change of dietary habits 
and restricting calorie and fat consumption 
are the most important actions to achieve 
sustained weight loss. Moreover, control of 
carbohydrate intake also has important role. 
Simple carbohydrates with a high glycemic 
index will cause additional metabolic load 
to patients. 
- Physical activity. Increased physical activity 
is also important in maintaining weight 
loss. Regular physical activity improves 
insulin resistance, reduces insulin level in 
patients with hyperinsulinemia, improves 
dyslipidemia and lowers blood pressure. 
Physical activity increases metabolic activity 
of muscle tissue and improves cardiovascular 
health in general. Increased physical acitivity 
also reduces the risk of T2DM. Moderate 
physical activity (brisk exercise) of at least 
30-60 minutes (brisk walking, swimming, 
cycling, dancing) for at least 4 days of the 
week, may reduce the risk of diabetes by 
35-40%. The determination of physical 
activity should consider the condition of 
patient comprehesnsively and identification 
of any contraindication is a very essential 
issue. For patients who have had usual 
sedentary lifestyle, exercise program should 
be initiated slowly and increased gradually. 
- Pharmacological intervention. The IDF 
recommend that when lifestyle intervention 
alone has not achieved adequate desired 
weight loss, and/or improved glucose 
tolerance, then metformin at the dose of 2 x 
250-850 mg/day (depending on tolerance) 
should be considered as a diabetes prevention 
strategy. Pharmacological therapy with 
metformin is aimed for patients aged <60 
years with BMI >30 kg/m2 (in Indonesia, 
BMI >25 kg/m2) and FPG >110 mg/
dl (6.1 mmol/l) who do not have any 
contraindication. For those who consume 
large amount of carbohydrates in their diet, 
acarbose is worthy of consideration to be the 
first line drug. Acarbose can be administered 
at the dose of 3 x 50 mg/day taken during 
the meal and the dose can be increased up 
to 3 x 100 mg/day. Peroxisome proliferator 
activated receptor-g agonist (PPARg) had 
shown promising results, but its side-effects 
on weight gain and congestive heart failure 
has become a great concern and its routine 
use is not recommended.A further option for 
the obese patients is orlistat. Newer agents 
such as rimonabant has also been very 
promising, but long-term safety and efficacy 
data on diabetes prevention are lacking and 
it is not recommended for prevention in 
individuals at high risk.8,17
(All) Population Approach
In planning the national prevention 
measures, both population groups should be 
targeted simultaneously. Moreover, all important 
activities should be adjusted to the characteristic 
local situation. The aim of population approach 
is to bring important changes in the health of 
a large percentage of population. It is based 
on promoting healthy lifestyle which is quite 
effective in preventing T2DM, including 
cardiovascular disease, hypertension, and 
many other non-communicable and chronic 
diseases. The most dominant effect of obesity is 
to induce glucose intolerance along with all of 
its consequences. The occurrence of epidemic 
diabetes can only be prevented by substantial 
lifestyle modification and it must be performed 
immediately. The prevention of T2DM is based 
on an increase in daily activity and healthier 
eating habits, thus resulting in a better balance 
between energy intake and energy utilization.8
Population approach to prevent diabetes 
according to the IDF recommendation based on 
results of lifestyle prevention studies:
- Everyone is encouraged to perform moderate 
physical activity (e.g. brisk walking) at least 
4 times of the week. 
- Everyone is encouraged to maintain a healthy 
weight. 
- Adults with BMI >23/kg/m2 should be 
encouraged to achieve and maintain a healthy 
weight and/or 5-10% weight reduction
- Children should be encouraged to achieve 
and maintain the normal range weight for 
height. 
- The approach taken needs to be culturaly 
sensitive. Cultural beliefs (e.g. about obesity) 
have to be understood and addressed.8
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The National Diabetes Prevention Plans 
should include:
1. Advocacy for community groups by 
supporting national associations and non-
government organizations. 
2. Community support on :
- Providing education at school about 
nutrition and physical activity
- Promoting opportunities for physical 
acitivity through urban design (e.g. 
improving the facilities for walking, 
cycling and play grounds)
- Supporting sports facilities for the general 
population
3. Fiscal and legislative / regulation policy, by:
- ‘Organizing’ food pricing, labeling and 
advertising
- E n f o r c i n g  e n v i r o n m e n t a l  a n d 
infrastructure regulation (e.g. urban 
planning and transportation policy to 
enchance physical activity)
4. Engagement of private sector 
- Promoting health in the workplace 
- Ensuring healthy food policies in food 
industry
5. Utilization of communication media (press, 
TV, radio) to improve the level of knowledge 
and motivation of the community.8
RECOMMENDATION 
General Recommendation 
1. Prediabetes may be associated or increase 
the risk of cardiovascular disease and 
microvascular complication and will progress 
to type-2 diabetes; therefore, it should be 
managed appropriately. 
2. All patients with prediabetes must receive 
adequate treatment including intensive 
lifestyle changes, which is safe and effective 
in order to improve the glycemic condition 
and to reduce cardiovascular risk.
Target
1. Target blood glucose level in subjects with 
prediabetes is similar to those with diabetes 
(A1c < 6.5%, FBG < 100 mg/dl, 2-hour 
postprandial blood glucose (PPBG) < 140 
mg/dl 
2. Target lipid level in subjects with prediabetes 
is similar to those with diabetes (triglycerides 
<130 mg/dl, HDL >45 mg/dl, LDL <100 mg/
dl)
3. Target blood pressure in subjects with 
prediabetes is similar to those with diabetes 
(sistolik <130 mmHg, diastolic <80 mmHg)
Diet
Recommended diet is low fat, low saturated 
fat and trans-fatty acid and low sodium intake. 
Avoid alcohol intake and get an adequate fiber 
intake.
Physical activities 
1. Individuals with prediabetes need to have 
5-10% weight loss of their initial weight and 
maintain their weight for long-term period
2. Regular and moderate physical activities are 
recommended for 30-60 minutes daily and it 
should be performed at least 4 days in a week.
Pharmacological treatment
1. In individual with prediabetes at high risk, 
pharmacological treatment is considered as 
adjuvant treatment of lifestyle modification/
changes. 
2. No drug has been approved today by the Food 
Drug Administration (FDA) for prediabetes; 
therefore, the decision for treatment is based 
on risk-benefit analysis
3. Metformin and acarbose are safe and 
effective to help preventing diabetes
4. Although thiazolidinediones reduces the risk 
of prediabetes progression to diabetes, but 
there is a risk of developing congestive heart 
failure and fracture that should be concerned. 
5. Statins are recommended to achieve treatment 
target of LDL cholesterol (<100 mg/dl), 
nonHDL (<130 mg/dl), and apolipoprotein 
B (<90 mg/dl)
6. In some patients,  fibrate, bile acid 
sequestrants, ezetimibe and other drugs may 
be beneficial as adjuvant treatments. 
7. Niacin improves lipid profile but it has a 
potency to cause glycemic effect
8. When there is a hypertension, angiotensin-
converting enzyme inhibitors or angiotensin 
receptor blockers are recommended as the 
first line treatment and calcium channel 
blockers are recommended as the second 
line.
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9. Thiazides and/or b-blocker are utilized by 
taking the effect of glycemia into account 
10. All individuals with prediabetes who have no 
risk of gastrointestinal, intracranial or other 
bleeding should receive low-dose aspirin. 
Monitoring 
1. Monitoring of patients with prediabetes 
includes annual OGTT and microalbuminuria 
examination. Investigations on FBG, HbA1c 
and lipid levels are performed at least twice 
a year.
2. For patients at a very high risk, monitoring 
must be performed more often.
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